CA2323237C - Methodes ameliorees de radiotherapie - Google Patents

Methodes ameliorees de radiotherapie Download PDF

Info

Publication number
CA2323237C
CA2323237C CA002323237A CA2323237A CA2323237C CA 2323237 C CA2323237 C CA 2323237C CA 002323237 A CA002323237 A CA 002323237A CA 2323237 A CA2323237 A CA 2323237A CA 2323237 C CA2323237 C CA 2323237C
Authority
CA
Canada
Prior art keywords
seq
aii
radiation
pro
damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002323237A
Other languages
English (en)
Other versions
CA2323237A1 (fr
Inventor
Kathleen E. Rodgers
Gere Dizerega
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Priority to CA2659664A priority Critical patent/CA2659664C/fr
Publication of CA2323237A1 publication Critical patent/CA2323237A1/fr
Application granted granted Critical
Publication of CA2323237C publication Critical patent/CA2323237C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/32—Angiotensins [AT], angiotensinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des méthodes et trousses destinées à atténuer les dégâts causés aux tissus par un rayonnement, à améliorer l'efficacité de la radiothérapie, à faciliter une greffe de moelle osseuse et à favoriser la production et la mobilisation de mégacaryocytes et la production de plaquettes; chaque méthode consiste à administrer une quantité effective d'angiotensinogène, d'angiotensine I (AI), d'analogues d'AI, de fragments d'AI et de leurs analogues, d'angiotensine II (AII), d'analogues d'AII, de fragments d'AII ou de leurs analogues ou d'agonistes de récepteur d'AII AT2 de type 2.
CA002323237A 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie Expired - Fee Related CA2323237C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2659664A CA2659664C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US7738298P 1998-03-10 1998-03-10
US60/077,382 1998-03-10
US8126298P 1998-04-09 1998-04-09
US60/081,262 1998-04-09
US8367098P 1998-04-30 1998-04-30
US60/083,670 1998-04-30
US9009698P 1998-06-19 1998-06-19
US60/090,096 1998-06-19
US9021698P 1998-06-22 1998-06-22
US60/090,216 1998-06-22
US9995798P 1998-09-11 1998-09-11
US60/099,957 1998-09-11
PCT/US1999/005194 WO1999045945A1 (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2659664A Division CA2659664C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Publications (2)

Publication Number Publication Date
CA2323237A1 CA2323237A1 (fr) 1999-09-16
CA2323237C true CA2323237C (fr) 2009-05-19

Family

ID=27557165

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002323237A Expired - Fee Related CA2323237C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie
CA2659664A Expired - Fee Related CA2659664C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2659664A Expired - Fee Related CA2659664C (fr) 1998-03-10 1999-03-08 Methodes ameliorees de radiotherapie

Country Status (5)

Country Link
EP (1) EP1061937A1 (fr)
JP (1) JP3728400B2 (fr)
AU (1) AU744799B2 (fr)
CA (2) CA2323237C (fr)
WO (1) WO1999045945A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
AU2002308522A1 (en) * 2001-05-01 2002-11-11 University Of Southern California Methods for inhibiting tumor cell proliferation
CN1529697B (zh) 2001-05-31 2010-09-22 维科尔药物公司 用作血管紧张素ⅱ激动剂的三环化合物
WO2011120032A1 (fr) 2010-03-26 2011-09-29 University Of Southern California Méthodes pour traiter des lésions combinées de radiation et thermiques
EP2555760B1 (fr) 2010-04-06 2019-10-16 Synedgen, Inc. Derives de chitosane pour le traitement de la mucosite ou de l'ulceration
JP2013533315A (ja) * 2010-08-10 2013-08-22 ユニバーシティー オブ サザン カリフォルニア 細胞移植における、及びノロウイルス感染症を防止／治療する薬剤としてのアンジオテンシンｉｉ（１−７）の使用
EP2455388A1 (fr) 2010-11-23 2012-05-23 LanthioPep B.V. Nouveaux agonistes du récepteur 2 (AT2) de type angiotensine et leurs utilisations
US20150050250A1 (en) * 2012-04-05 2015-02-19 University Of Southern California Cell therapy technology to deliver radio-protective peptides
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
WO2014047506A1 (fr) 2012-09-20 2014-03-27 Synedgen, Inc. Procédés pour le traitement ou la prévention de dommages résultant d'un rayonnement, d'un trauma ou d'un choc
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
EP4007592A1 (fr) 2019-08-02 2022-06-08 LanthioPep B.V. Agonistes du récepteur de l'angiotensine 2 (at2) destinés à être utilisés dans le traitement du cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE457055B (sv) * 1986-08-18 1988-11-28 Ferring Ab Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser
US5015629A (en) * 1989-06-26 1991-05-14 University Of Southern California Tissue repair
WO1995008565A1 (fr) * 1993-09-24 1995-03-30 The University Of Southern California Utilisation d'analogues d'angiotensine ii pour la reparation tissulaire
WO1997034627A2 (fr) * 1996-03-19 1997-09-25 Societe De Conseils De Recherches Et D'applications Scientifiques S.A. Protection de cellules hematopoietiques durant une chimiotherapie ou une radiotherapie

Also Published As

Publication number Publication date
AU744799B2 (en) 2002-03-07
WO1999045945A1 (fr) 1999-09-16
EP1061937A1 (fr) 2000-12-27
CA2323237A1 (fr) 1999-09-16
JP2002506042A (ja) 2002-02-26
AU2995799A (en) 1999-09-27
JP3728400B2 (ja) 2005-12-21
CA2659664A1 (fr) 1999-09-16
CA2659664C (fr) 2013-05-07

Similar Documents

Publication Publication Date Title
US7776828B2 (en) Radiation therapy methods
US6455500B1 (en) Radiation therapy methods
CA2319701C (fr) Procede pour promouvoir l'erythropoiese
AU737058B2 (en) Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US7786085B2 (en) Method for treating a patient undergoing chemotherapy
AU759285B2 (en) Methods to increase white blood cell survival after chemotherapy
CA2323237C (fr) Methodes ameliorees de radiotherapie
US6762167B1 (en) Methods for treating a patient undergoing chemotherapy
MXPA00008843A (en) Improved radiation therapy methods
EP1410801B1 (fr) Procédé favorisant la prolifération et la différentiation des cellules hématopoitiques
MXPA00011112A (en) Methods to increase white blood cell survival after chemotherapy
MXPA00007509A (en) Method of promoting erythropoiesis

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160308